Substituted benzamides, their production and their use as cysteine protease inhibitors
申请人:Abbott Laboratories
公开号:US06436925B1
公开(公告)日:2002-08-20
Benzamides of the formula I
and its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the following meanings:
R1—C1-C6-alkyl, branched or unbranched, where one of the C atoms in this chain may be substituted by a phenyl ring, cyclohexyl ring, indolyl ring and an SCH3 group, and the phenyl ring in turn is substituted by by [sic] a maximum of two R4 radicals, where R4 [lacuna] hydrogen, C1-C4-alkyl, branched or unbranched, —O—C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO—C1-C4-alkyl, NHCO—C1-C4-alkyl, and
R2 can be NR5CO—R6 and NHR5SO2—R6, and
R3 is chlorine, bromine, fluorine, C1-C6-alkyl, NHCO—C1-C4-alkyl, NHSO2—C1-C4-alkyl, NO2, —O—C1-C4-alkyl, CN, COOH, CONH2, COO—C1-C4-alkyl, SO2—C1-C4-alkyl, —SO2Ph, SO2NH—C1-C4-alkyl, iodine, SO2NH2 and NH2, and
A can be aromatic rings and heteroaromatic rings such as naphthyl, quinolyl, quinoxyl, benzimidazolyl, benzothienyl, quinazolyl, phenyl, thienyl, imidazolyl, pyridyl, pyrimidyl and pyridazyl, it also being possible for the rings to be substituted by by [sic] R9 and up to 2 R8 radicals, and
B a bond, —(CH2)m—, —(CH2)m—O—(CH2)o—, —(CH2)o—S—(CH2)m—, —(CH2)o—SO—(CH2)m—, —(CH2)o—SO2—(CH2)m—, —CH═CH—, —C≡C—, —CO—CH═CH—, —(CH2)o—CO—(CH2)m—, —(CH2)m—NHCO—(CH2)o—, —(CH2)m—CONH—(CH2)o—, —(CH2)m—NHSO2—(CH2)o—, —NH—CO—CH═CH—, —(CH2)m—SO2NH—(CH2)o—,
A—B together also
R5 hydrogen and C1-C4-alkyl and
R6 is hydrogen, phenyl, naphthyl, C1-C6-alkyl, linear or branched, it being possible for a C atom in the chain to be substituted by a phenyl ring which itself may also be substituted by one or two R4 radicals, and
R8 can be hydrogen, C1-C4-alkyl, branched or unbranched, —O—C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO—C1-C4-alkyl, —NHCO—C1-C4-alkyl, phenyl, NHCO-phenyl, —NHSO2—C1-C4-alkyl, —NHSO2-phenyl, —SO2—C1-C4-alkyl, pyridine [sic] and SO2-phenyl,
R9 hydrogen, —CHR14—(CH2)p—R12 where R12 pyrrolidine [sic], morpholine [sic], piperidine [sic], hexahydroazepine [sic], homopiperazine [sic],
and R10 [lacuna] C1-C6-alkyl, branched or unbranched, and which may also carry a phenyl ring which is in turn substituted by by [sic] a maximum of two R11 radicals, where R11 is hydrogen, C1-C4-alkyl, branched or unbranched, —O—C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO—C1-C4-alkyl, NHCO—C1-C4-alkyl, —NHSO2—C1-C4-alkyl and —SO2—C1-C4-alkyl; and
R13 is hydrogen and C1-C6-alkyl, branched or unbranched, and
n,p is [sic], independently of one another, a number 0, 1 or 2, and
m,o is [sic], independently of one another, a number 0, 1, 2, 3 or 4.
公式I的苯甲酰胺及其互变异构形式、可能的对映异构体和顺反异构体形式、E和Z形式,以及可能的生理上可耐受的盐,其中变量具有以下含义:R1—C1-C6-烷基,支链或直链,其中这条链中的一个C原子可能被苯环、环己基环、吲哚基和SCH3基取代,而苯环则被最多两个R4基取代,其中R4是氢、C1-C4-烷基、支链或直链、—O—C1-C4-烷基、羟基、氯、氟、溴、碘、三氟甲基、硝基、氨基、氰基、羧基、—COO—C1-C4-烷基、NHCO—C1-C4-烷基;R2可以是NR5CO—R6和NHR5SO2—R6;R3是氯、溴、氟、C1-C6-烷基、NHCO—C1-C4-烷基、NHSO2—C1-C4-烷基、硝基、—O—C1-C4-烷基、氰基、羧基、酰胺、—COO—C1-C4-烷基、SO2—C1-C4-烷基、—SO2Ph、SO2NH—C1-C4-烷基、碘、SO2NH2和氨基;A可以是芳香环和杂环,如萘基、喹啉基、喹氧基、苯并咪唑基、苯并噻吩基、喹唑基、苯基、噻吩基、咪唑基、吡啶基、嘧啶基和吡啶二唑基,环也可能被最多两个R8基取代;B是键、—(CH2)m—、—(CH2)m—O—(CH2)o—、—(CH2)o—S—(CH2)m—、—(CH2)o—SO—(CH2)m—、—(CH2)o—SO2—(CH2)m—、—CH=CH—、—C≡C—、—CO—CH=CH—、—(CH2)o—CO—(CH2)m—、—(CH2)m—NHCO—(CH2)o—、—(CH2)m—CONH—(CH2)o—、—(CH2)m—NHSO2—(CH2)o—、—NH—CO—CH=CH—、—(CH2)m—SO2NH—(CH2)o—,A—B共同也是R5氢和C1-C4-烷基,R6是氢、苯基、萘基、C1-C6-烷基,直链或支链,链中的一个C原子可以被苯环取代,而苯环本身也可能被一个或两个R4基取代;R8可以是氢、C1-C4-烷基、支链或直链、—O—C1-C4-烷基、羟基、氯、氟、溴、碘、三氟甲基、硝基、氨基、氰基、羧基、—COO—C1-C4-烷基、苯基、NHCO-苯基、—NHSO2—C1-C4-烷基、—NHSO2-苯基、—SO2—C1-C4-烷基、吡啶及苯基,R9是氢、—CHR14—(CH2)p—R12,其中R12是吡咯烷、吗啉、哌啶、六氢异氮杂环、异哌嗪,R10是C1-C6-烷基,支链或直链,也可能携带一个可能被最多两个R11基取代的苯环,其中R11是氢、C1-C4-烷基、支链或直链、—O—C1-C4-烷基、羟基、氯、氟、溴、碘、三氟甲基、硝基、氨基、氰基、羧基、—COO—C1-C4-烷基、NHCO—C1-C4-烷基、—NHSO2—C1-C4-烷基和—SO2—C1-C4-烷基;R13是氢和C1-C6-烷基,支链或直链;n,p分别是0、1或2;m,o分别是0、1、2、3或4。